ANALYSES OF GENOMIC IMPRINTING IN CHROMOSOME TRANSLOCATIONS OF HEMATOLOGIC NEOPLASIA
ANALYSES OF GENOMIC IMPRINTING IN CHROMOSOME TRANSLOCATIONS OF HEMATOLOGIC NEOPLASIA
批准号:
06671100
负责人:
TOMONAGA Masao
金额:
$1.34万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
1994
资助国家:
日本
项目状态:
已结题
起止时间:
1994 至 1996
中文摘要
点击翻译按钮获取中文摘要
英文摘要
It has been controversial in Ph-positive chronic myeloid leukemia (CML) whether the rearranged chromosomes 9 and 22 have 'parent of origin'bias. In this study, we investigated parental origin not only of rearranged chromosomes 9 and 22 in Ph-positive CML by C-banding and Ag-I-staining methods, respectively, but also of rearranged chromosome 21 in t (8 ; 21) -positive acute myeloid leukemia (AML) and of rearranged chromosome 15 in t (15 ; 17) -positive AML by Ag-I-staining method. As a result, it was disclosed that among five Ph-positive CML patients one had paternal rearranged chromosomes 9 and maternal rearranged chromosome 22, one maternal rearranged chromosomes 9 and paternal rearranged chromosome 22, and one undetermined rearranged chromosomes 9 and maternal rearranged chromosome 22. Among seven t (8 ; 21) -postitive AML patients, one had paternal rearranged chromosome 21 and three maternal one. Among six t (15 ; 17) -positive AML patients, two had paternal rearranged chromosome 15 and one maternal one. In 1992, Haas et al.indicated that in Ph-positive CML rearranged chromosomes 9 and 22 are exclusively paternal and maternal in origin, respectively, by C-banding and Ag-I-staining methods. However, several reports which investigated the parental origin of the rearranged chromosomes by molecular methods did not support the Haas's hypothesis. Our results indicate that there is no parental bias, i.e., genomic imprinting, in the origin not only of ABL and M-BCR which are rearranged in Ph-positive CML,but also of AML-1 and PML in t (8 ; 21) -and t (15 ; 17) -associated AMLs, respectively.
期刊论文(5)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
Y.Shimamoto: "Prophylaxis of Symptoms of Hyperhistaminemia after the Treatment of Acute Promyelocytic Leukemia with All-Trans Retioic Acid" Acta Haematologica. 92. 109-112 (1994)
Y.Shimamoto:“用全反式维甲酸治疗急性早幼粒细胞白血病后高组胺血症症状的预防”《血液学报》。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
中村 秀男: "Morphological subtyping of acute leukemia with maturation (AML-M2) : homogeneous pink-colored cytoplasm of mature neutrophils is most charateristic of AML-M2 with t(8;21)." LEUKEMIA. (発表予定).
Hideo Nakamura:“成熟型急性白血病 (AML-M2) 的形态学亚型:成熟中性粒细胞的均匀粉红色细胞质是 t(8;21) AML-M2 的最大特征。”
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Dale L.Preston: "Cancer Incidence in Atomic Bomb Survivors. Part III:Leukemia,Lymphoma and Multiple Myeloma, 1950-1987" RADIATION RESEARCH. 137. 68-97 (1994)
Dale L.Preston:“原子弹幸存者的癌症发病率。第三部分:白血病、淋巴瘤和多发性骨髓瘤,1950-1987 年”辐射研究。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Hideo Nakamura, Kazutaka Kuriyama, Naoki Sadamori, Mariko Mine, Takahiro Itoyama, Ippei Sasagawa, Kazuhiro Matsumoto, Yoshiro Tsuji, Norio Asou, Shin-IchiKageyama, Hisashi Sakamaki, Nobuhiko Emi, Ryuzo Ohno, and Masao Tomonaga: "Morphological Subtyping of
Hideo Nakamura、Kazutaka Kuriyama、Naoki Sadamori、Mariko Mine、Takahiro Itoyama、Ippei Sasakawa、Kazuhiro Matsumoto、Yoshiro Tsuji、Norio Asou、Shin-IchiKageyama、Hisashi Sakamaki、Nobuhiko Emi、Ryuzo Ohno 和 Masao Tomonaga:“形态学子类型化
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
中村秀男: "Morphological subtyping of acute myeloid leukemia with maturation(AML-M2) : homogeneous pinkcolored cytoplasm of mature neutrophils is most charateristic of AML-M2 with t(8;21)." LEUKEMIA. (in press).
Hideo Nakamura:“成熟型急性髓性白血病 (AML-M2) 的形态学亚型:成熟中性粒细胞的均质粉红色细胞质是 t(8;21) AML-M2 的最具特征性。”
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Comparative study of refractory anemia(FAB)of MDS in clinical features between Japan and China Cooperative Group
-
批准号:18406033
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$4.14万
-
财政年份:2006
-
负责人:TOMONAGA Masao
-
依托单位:
Development of a new classification for AML based on the gene expression profile in leukemia stem cells.
-
批准号:15390303
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$3.01万
-
财政年份:2003
-
负责人:TOMONAGA Masao
-
依托单位:
Significance of autocrine mechanism of VEGF/VEGF receptor in ATL cell proliferation.
-
批准号:13671069
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.3万
-
财政年份:2001
-
负责人:TOMONAGA Masao
-
依托单位:
Analysis of proviral and cellular genome abnormalities found during disease progression in adult T-cell leukemia/lymphoma
-
批准号:09671122
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$1.79万
-
财政年份:1997
-
负责人:TOMONAGA Masao
-
依托单位:
国内基金
登录
查看更多内容
基于高分辨率增强子-启动子互作图谱解析t(8:21)劫持的增强子对白血病发生发展的调控机制
-
批准号:--
-
项目类别:青年科学基金项目
-
资助金额:--
-
批准年份:2024
-
负责人:侯骅
-
依托单位:
索拉非尼靶向c-Kit抑制Skp2介导的DNA损伤修复增强阿糖胞苷对t(8;21)急性髓系白血病细胞杀伤及机理研究
-
批准号:82370152
-
项目类别:面上项目
-
资助金额:49万元
-
批准年份:2023
-
负责人:史鹏程
-
依托单位:
t(8;21)阳性急性髓系白血病红系分化阻滞的机制研究与分化诱导疗法的探讨
-
批准号:82300198
-
项目类别:青年科学基金项目
-
资助金额:30万元
-
批准年份:2023
-
负责人:王梦溪
-
依托单位:
AML1-ETO/SETD8新型复合体增强染色质可及性维持t(8;21)AML白血病干细胞干性的新机制
-
批准号:82304555
-
项目类别:青年科学基金项目
-
资助金额:20万元
-
批准年份:2023
-
负责人:苏永伟
-
依托单位:
双靶向AML1-ETO融合癌蛋白与c-Kit突变体治疗t(8;21)急性髓系白血病的分子机制研究
-
批准号:82370151
-
项目类别:面上项目
-
资助金额:49万元
-
批准年份:2023
-
负责人:俞文娟
-
依托单位:
异质性CD34+CD117dim原始细胞亚群致t(8;21)AML不良预后的机制研究
-
批准号:82300184
-
项目类别:青年科学基金项目
-
资助金额:30万元
-
批准年份:2023
-
负责人:李雪萍
-
依托单位:
表观遗传调控基因PHF6在t(8;21)急性髓系白血病中作用机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:汪晓敏
-
依托单位:
AML1-ETO/CDK12复合物促进超级增强子活性维持t(8;21)急性髓系白血病干细胞干性的机制研究
-
批准号:82270172
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:周景峰
-
依托单位:
AML1-ETO融合蛋白调控NR4A2的表观遗传学沉默促进t(8;21)急性髓系白血病发生发展的分子机制研究
-
批准号:--
-
项目类别:青年科学基金项目
-
资助金额:30万元
-
批准年份:2022
-
负责人:黄赛
-
依托单位:
TGF-β1调控CD8+T细胞功能耗竭介导的t(8;21)急性髓系白血病免疫逃逸机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:李雪萍
-
依托单位: